Indications and prescribing patterns of antiseizure medications in children in New Zealand

Abstract

AbstractAimTo determine indications and prescribing patterns for antiseizure medications (ASMs) in children by age, sex, and socioeconomic status.MethodThis retrospective study searched the New Zealand database of ASM prescriptions dispensed to individuals aged 18 years or under during 2015 in three regions of New Zealand (48% paediatric population). Medical records were reviewed by a paediatric neurologist for indication. ASMs were grouped into old or new (1993 onwards).ResultsIn total, 2594 children (0 to 18 years, mean age 11 years 2 months, median 12 years; 51% male) were dispensed 3557 ASMs for seizures (76%), pain (6%), headache (5%), mental health (3%), and movement disorders (2%). After 10 years of age, lamotrigine was more likely and valproate less likely to be prescribed in females than males. No sex difference was observed for valproate prescriptions for non‐seizure indications. Topiramate prescriptions increased in adolescent females. Prescriptions for non‐seizure indications increased from 7% in children aged 6 years or under to 31% in 16‐ to 18‐year‐olds. The proportion of children receiving a new ASM compared to an old ASM was greater in children from higher than lower socioeconomic areas.InterpretationOur results highlight a need for focused ASM teratogenicity messaging to clinicians prescribing ASMs for non‐seizure indications. In addition, to improve equity of epilepsy care, it is critical for health policies to consider socioeconomic factors that impact on ASM prescribing.